AbbVie Reports P-IIa (TARGET-CD) Data of ABBV-466 for Moderate to Severe Crohn’s Disease at UEGW 2026

Shots: AbbVie has reported data from the open-label, treat-through P-IIa platform (TARGET-CD) study of ABBV-466 (n=106) vs risankizumab (anti-IL-23 p19; n=94) or trosunilimab (anti-α4β7; n=100) monotherapy for 24wks. in pts (N=300) with moderately to severely active CD, of whom 75% had failed ≥1 advanced therapy; data were presented as a late-breaking abstract at UEGW 2026 on Oct 19, 2026 ABBV-466 achieved endoscopic remission (1EP) at Wk. 12 in 30.2% of pts vs 21.3% (risankizumab) & 18.0% (trosunilimab), rising to 40.5% vs 22.4% & 20.0% at Wk. 24; gene expression analyses showed colonic epithelial repair & barrier restoration at Wk. 12, followed by tissue remodeling & metabolic changes at Wk. 24 SAE rates were 10.4% with ABBV-466 vs 9.6% (risankizumab) & 9.0% (trosunilimab), with CD & nausea the most common AEs (≥5%) in the ABBV-466 arm; ABBV-466 is an investigational dual-targeting therapy combining risankizumab with trosunilimab, designed to inhibit inflammatory signaling while limiting immune-cell trafficking to the gut Ref: PR Newswire  |   Image: AbbVie  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post AbbVie Reports P-IIa (TARGET-CD) Data of ABBV-466 for Moderate to Severe Crohn’s Disease at UEGW 2026 appeared first on PharmaShots.